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Medicines receiving a conditional marketing authorization through Medicines Adaptive
Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of
MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli,
with payers not consulted or involved. However, once medicines are approved through
MAPPs, they will be evaluated for funding by payers through different activities. These
include Health Technology Assessment (HTA) with often immature clinical data and
high uncertainty, financial considerations, and negotiations through different types
of agreements, which can require monitoring post launch. Payers have experience
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with new medicines approved through conditional approval, and the fact that MAPPs
present additional challenges is a concern from their perspective. There may be some
activities where payers can collaborate. The final decisions on whether to reimburse
a new medicine via MAPPs will have more variation than for medicines licensed via
conventional processes. This is due not only to increasing uncertainty associated with
medicines authorized through MAPPs but also differences in legal frameworks between
member states. Moreover, if the financial and side-effect burden from the period of
conditional approval until granting full marketing authorization is shifted to the post-
authorization phase, payers may have to bear such burdens. Collection of robust data
during routine clinical use is challenging along with high prices for new medicines during
data collection. This paper presents the concept of MAPPs and possible challenges.
Concerns and potential ways forward are discussed and a number of recommendations
are presented from the perspective of payers.
Keywords: European Medicines Agency, Adaptive Pathways, Health Technology Assessment, marketing
authorization, payers
INTRODUCTION
Fifty years from the introduction of Council Directive
65/65/EEC1, there seems to be consensus from different
stakeholders that despite considerable achievements, the
pharmaceutical framework still has room for improvement.
Existing gaps include a lack of the full achievement of the
objectives as set out by the Treaties, problems with the
availability and affordability of medicines for all citizens of the
European Union (EU), the need for incentives for innovation,
and the need for increased development of pathways for access
to medicines for rare diseases that address unmet medical
need (Heads of Medicines Agencies, 2007; Commission of the
European Communities, 2008; Matrix Insight, 2012; Council of
the EU, 2016).
Minimizing health care disparities is fundamental for the
equitable and progressive achievement of universal health
coverage. There are concerns that the rate at which new
medicines are introduced may vary, in particular that new
treatments may be taken up less quickly and in lower numbers
in certain countries due to challenges in access, availability and
affordability (Putrik et al., 2014; UK, 2016). Equity is an ethical
concept which is based on the principle of distributive justice and
refers to social justice or fairness (Rawls, 1971; Sen, 2010). Equity
in health can largely be defined as the absence of systematic
disparities in health between social groups who have different
levels of underlying social advantage or different positions in
social hierarchy (Whitehead, 1991; Culyer, 1993; Oliver, 2004;
Hosseinpoor et al., 2014).
Access to medicines in therapeutic areas with unmet medical
need typically has a high public health value. Over the
years, there have been various legislative and non-legislative
initiatives to address this issue. The European Medicines Agency
(EMA) included the objective of earlier access to medicines
1Council Directive 65/65/EEC of 26 January 1965 on the approximation of
provisions laid down by Law, Regulation or Administrative Action relating to
proprietary medicinal products.
for unmet medical need in its priorities, and in recent years
has proposed “Adaptive Pathways”, also known as Medicines
Adaptive Pathways to Patients (MAPPs), as a key initiative to
address this. Adaptive Pathways are presented as an approach
intended to maximize the positive impact of new medicines on
public health, achieved by balancing the need for timely patient
access through staggered approval with iterative phases by using
existing tools combined with a more flexible use of the existing
regulatory framework (Eichler et al., 2012, 2013, 2015; European
Medicines Agency, 2014; Rasi and Eicher, 2016).
Through Adaptive Pathways, a medicine can follow an
“iterative” process whereby it can initially be approved only for
a smaller group of patients (based on limited scientific evidence)
and then, when more evidence is gathered, the medicine will be
more widely approved. Moreover, a medicine could be approved
on the basis of surrogate endpoints, which would need to be
verified later with more clinically important outcome endpoints
(Ermisch et al., 2016).
Payers support innovation and access to new effective
medicines, especially where there is true unmet medical need,
as illustrated by initiatives in the UK to accelerate access
to new innovative medicines (UK, 2016). In practice though,
only a limited number of new medicines are truly innovative
and address real gaps in treatment (Garattini et al., 2008;
Ermisch et al., 2016; Prescrire Editorial, 2016). As a result,
and when combined with the many challenges involved, payers
and others have concerns with the concept of Adaptive
Pathways as proposed by the EMA. These concerns have
been summarized and published in a series of papers (Banzi
et al., 2015; Joint Briefing Paper, 2015; Joint response to
EMA public consultation, 2015; Cattarin, 2016; Davis et al.,
2016; Ermisch et al., 2016; Garattini et al., 2016; Hawkes,
2016a,b; Natsis, 2016). These concerns were aggravated by
the lack of clear justification for the need of Adaptive
Pathways over and above the available regulatory processes (Joint
Briefing Paper, 2015; Ermisch et al., 2016; Joint Press Release,
2016).
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A major step in the MAPPs initiative was the publication
of the “Final report on the adaptive pathways pilot” (European
Medicines Agency, 2016). This report showed that in spite
of the concerns expressed by key stakeholders, the EMA was
pushing forward with the MAPPs concept. Issues identified for
further reflection included a proposal for the involvement of
all key stakeholders [patients, healthcare professionals, Health
Technology Assessment (HTA) bodies and payers]. EMA
“expected” the various stakeholders to cooperate to ensure
timely and affordable access to new innovative medicines.
Unfortunately, payers were not involved in the process of
Adaptive Pathways and, in the report of the pilot, the EMA only
considered to invite payers to come on board “if relevant”. At
this stage, the EMA only considered possible “fine-tuning” of the
concept. In next steps, the possible incorporation of Adaptive
Pathways into existing platforms for parallel regulatory-HTA
scientific advice was to be investigated (European Medicines
Agency, 2016).
As a result, payers need to plan and be prepared for evaluation
of medicinal products with a European conditional marketing
authorization through the Adaptive Pathways concept especially
if higher prices are requested vs. current standards. As the
concept of Adaptive Pathways was an initiative to improve access
to medicines for unmet medical need, it will be important to
measure the level of the true achievement of this objective in
the future. This is a prerequisite to allow any considerations by
payers.
The objective of this paper is to consider possible next steps
and alternatives for payers in preparation for the potential
implementation of the concept of Adaptive Pathways.
THE PHARMACEUTICAL FRAMEWORK IN
EUROPE
The pharmaceutical framework encompasses a complex real-life
set of systems.
It consists of a series of parallel and consecutive systems,
which although independent in structure and function, are
highly influential on each other. These systems differ in order
and function between Member States but generally follow
similar activities. These include research and development,
evaluation and marketing authorization, post-authorization
monitoring, setting of prices, manufacture and supply,
HTA and reimbursement, procurement, provision of health
services, prescribing and dispensing, administration, and
use of medicines. Within the confines of the current legal
structure, the pharmaceutical framework is constantly evolving
through the initiatives of the different stakeholders who set
policies, introduce activities and build structures for their
functioning within the pharmaceutical framework. The final
outcomes of the framework depend on the outcomes of the
individual systems and also on the logical flow from one system
to another, which can be blocked at any system within the
framework, affecting the systems which follow it and also
possibly those which come before it (Vella Bonanno, 2003,
2010).
FRAMEWORK, INITIATIVES AND TOOLS
SUPPORTING THE EARLY ACCESS OF
MEDICINAL PRODUCTS
Legal and Governance Structure
The Treaties of the EU set the mandate for the structure
and systems of the pharmaceutical framework, including the
competences and responsibilities of the EU and the Member
States and the balances between them. The main objective of
the framework is a high level of protection of human health and
the improvement of public health. The Treaties clarify principles
including the principle of subsidiarity and the principle of
conferral. The principle of subsidiarity determines when the
EU is competent to legislate, while the principle of conferral
states that the EU shall act within the limits of the competences
conferred to it by the Member States in the Treaties, and that
the competences not conferred upon the Union by the Treaties
remain within the Member States2. The European Commission
(EC), the European Parliament, and the Council can adopt
measures for setting high standards of quality and safety for
medicinal products (Council of the EU, 2016).
The main objective of European medicines regulation is
to ensure that available medicines are of good quality, safe
and efficacious. The bodies responsible for the regulation of
medicinal products consist of the network of the EMA and the
regulatory agencies in the individual member states. The EMA is
governed by Regulation (EC) No. 726/20043. The responsibility
for the regulatory benefit/risk governance of medicinal products
authorized through the centralized procedure lies with the EC.
The responsibility for the marketing authorization of medicinal
products receiving a national marketing authorization lies with
the licensing authority within the respective Member State. The
number of medicinal products approved through the centralized
procedure which are truly innovative is limited (Motola et al.,
2006).
There have been a number of updates to the pharmaceutical
legislation addressing unmet medical need. There were specific
changes to the legislation for centrally authorized products
(Regulation (EC) No. 726/2004) which allow for early access
of new medicinal products including conditional approval
[Article 14 (7)] and compassionate use (Article 83). Conditional
marketing authorization is part of the marketing authorization
decision and appreciably affects the post-authorization phase. In
specific situations of unmet medical need, and in the interest
of public health, the legislation provides the possibility for
granting conditional marketing authorizations on the basis of
less complete data than is required for a normal submission.
This still requires the assumption that the benefit/risk profile
2EUR-Lex Official Journal of the European Union, Treaty of Lisbon amending
the Treaty on European Union and the Treaty establishing the European
Community, Signed at Lisbon, 13 December 2007. OJC 306, 17.12.2007, p. 1-271,
Title II. http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.C_.2007.
306.01.0001.01.ENG&toc=OJ:C:2007:306:TOC#d1e13083-1-1 - same access date
3Regulation (EC) No. 726/2004 of the European Parliament and of the Council
of 31 March 2004 laying down Community procedures for the authorization and
supervision of medicinal products for human and veterinary use and establishing
the European Medicines Agency.
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is positive and that knowledge gaps will be closed. Following
conditional approval, the pertinent medicines should be subject
to obligations of fulfillment of the data requirements. The
marketing authorization is not meant to remain conditional
indefinitely (Regulation (EC) No. 507/2006)4. To date, the
experience with conditional approval has been modest. From
2006 to June 2014, 26 products were granted a conditional
marketing authorization and a number of these have not fulfilled
their post-authorization obligations (Banzi et al., 2015). A more
recent update published by the EMA reported that 30 products
were approved through conditional approval from 2006 to 30th
June 2016. By the date of publication in early 2017, eleven
of these approvals were converted into standard marketing
authorizations, two were withdrawn for commercial reasons and
seventeen were still conditional. Of the conditional marketing
authorizations, none were authorized for more than 5 years
(European Medicines Agency, 2017).
Compassionate use is an initiative which takes place prior
to marketing authorization. This initiative provides for the use
of a product eligible under the centralized procedure to be
available to a group of patients “with chronically or severely
debilitating disease or whose disease is considered to be life-
threatening and who cannot be treated satisfactorily by an
authorized medicinal product”. The medicinal product concerned
must either be considered for authorization in accordance with
the centralized procedure or must be undergoing clinical trials.
Regulation (EC) No. 141/20005 on orphan medicinal products
and Regulation (EC) No 1901/20066 on paediatric medicines
were aimed at supporting research and development for life-
threatening and rare diseases and for indications in children
respectively. New pharmacovigilance legislation came into force
in 2012 and provides for monitoring of safety aspects throughout
the medicine’s life-cycle (Regulation (EU) No. 1235/2010)7.
Pricing and Reimbursement of Medicinal
Products
The competence and responsibility for decisions regarding which
medicinal products are reimbursed and at what price, lie with the
Member States (Council of the EU, 2016). The whole procedure
is regulated by the “Transparency Directive” (Council Directive
89/105/EEC). A marketing authorization gives the right to the
marketing authorization holder (MAH) to submit an application
4Regulation (EC) No. 507/2006 on the conditional marketing authorization for
medicinal products for human use falling within the scope of Regulation (EC) No.
726/2004.
5Regulation (EC) No. 141/2000 of the European Parliament and of the Council of
16 December 1999 on orphan medicinal products.
6Regulation (EC) No. 1901/2006. Regulation (EC) No. 1901/2006 and Regulation
(EC) No 1902/2006 of the European Parliament and of the Council of 12 December
2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC)
No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC)
No. 726/2004.
7Regulation (EU) No. 1235/2010 of the European Parliament and of the Council
of 15 December 2010 amending, as regards pharmacovigilance of medicinal
products for human use, Regulation (EC) No. 726/2004 laying down Community
procedures for the authorisation and supervision of medicinal products for human
and veterinary use and establishing a EuropeanMedicines Agency, and Regulation
(EC) No. 1394/2007 on advanced therapy medicinal products.
for a marketing authorization in countries with a positive list, and
have this application evaluated within 90 to 180 days (Article 6).
National pharmaceutical reimbursement systems are
governed by national legislation and policies, which cover
mainly aspects which are of national jurisdiction such as
pricing and reimbursement procedures, national essential
medicines lists, medicine financing, and human resources
related to pharmaceutical activities. National stakeholders of
the pharmaceutical framework include Drugs and Therapeutics
Committees which can include different experts in the field,
policy makers, operators of the supply chain, health care
professionals and patients, and patient organizations (WHO,
2001). Certain Central and Eastern European countries currently
experience significant delays in the introduction of new
expensive innovative medicines on their positive medicines
lists. In some countries, marketing authorization holders are
not interested in launching certain products in less favorable
and attractive markets possibly due to economies of scale while
another reason for delays in the launch of new medicines on
national markets are stringent price controls alongside external
reference pricing (Heads of Medicines Agencies, 2007; Leopold
et al., 2012; Dimitrova et al., 2013; Kamusheva et al., 2013).
Member States differ in the criteria and the considerations
which are used in the evaluation of new medicines such
as the way in which they deal with off-label comparators,
subgroup analyses and the role of cost-effectiveness. These
include different requirements for comparators, and whether
health economic techniques are used in reimbursement decision
making such as cost/ QALY (quality adjusted life year), with
or without threshold levels; alternatively, assigning a level of
innovation in preparation for pricing discussions, and the
ability to restrict patients to defined sub-groups for funding
with or without managed entry agreements (Ferrario and
Kanavos, 2013; Godman et al., 2013b, 2016b,a; Malmstrom et al.,
2013; Paris and Belloni, 2013; Matusewicz et al., 2015; WHO,
2015).
Overall, accessibility and funding of new medicines does
vary among Member States, as seen with the anti-TNF alpha
medicines for rheumatoid arthritis and Crohn’s disease and new
treatments for hepatitis C, depending on available resources.
Similarly for existing medicines such as the proton-pump
inhibitors and statins with different patient co-payments and
prescribing restrictions between countries (Godman et al., 2010;
Putrik et al., 2014; de Bruijn et al., 2016; Garuoliene et al., 2016;
Kostic et al., 2017).
Consequently, there is no guarantee that marketing
authorization through the process of Adaptive Pathways
will result in earlier access to medicines in all Member States.
These delays may result in disparity of burden sharing and
impact on the implementation of Adaptive Pathways among the
different European countries.
As stated, currently there are different mechanisms for pricing
of medicines in Member States (Vogler, 2008; Simoens, 2010;
Godman et al., 2013a, 2016a; Vogler et al., 2014; Permanand
and Pedersen, 2015). Pricing negotiations with pharmaceutical
companies are conducted by one or more entities within each
Member State. At times, there is lack of trust between different
parties (Pharma Diplomacy Working Group, 2016). Concerns
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with trust are exacerbated by apparently limited correlation
between costs for research and development, the costs of
producing medicines, their value and the requested prices for
new medicines (Experts in CML, 2013; Kantarjian et al., 2013;
Paris and Belloni, 2013; Avorn, 2015; Gagnon, 2015; Godman
et al., 2015, 2016a; Mailankody and Prasad, 2015; de Bruijn
et al., 2016; Hill et al., 2017; Prasad et al., 2017). In view of the
different mechanisms, and in spite of external reference pricing,
European countries pay different prices for their medicinal
products (Kanavos et al., 2011; Leopold et al., 2012, 2013; Vogler
et al., 2017).
European health technology initiatives include the
development of HTA Networks at a strategic level and the
EUnetHTA Joint Action at a technical level. The HTA network
was established through Article 15 of Directive 2011/24/EU on
the application of patients’ rights in cross-border healthcare.
The EUnetHTA Joint Action is organized as a voluntary
network of national and regional HTA agencies and other HTA
organizations involved in pricing and reimbursement. The remit
of EUnetHTA includes the production of guidelines and the joint
assessment of health technologies. The funding for EUnetHTA
Joint Actions is secured up to 2020, and currently the EC is
conducting an exercise to study the future for collaboration on
HTA following this as part of their new initiative (European
Commission Public Health, 2016).
HTA based on evidence and the interpretation of clinical data
is designed to support decision making, including consideration
of reimbursement when resources are scarce. Overall, there are
different tools to support pricing and reimbursement decisions
and their monitoring (Paris and Belloni, 2013; Matusewicz et al.,
2015). HTA has also utilized multi-criteria decision analysis
(MCDA) for analyzing the value of medicines where more than
one criterion is relevant (Irwin and Peacock, 2015; Godman
et al., 2016a). MCDA is defined as a methodology for appraising
alternatives on individual criteria, and combining them into one
overall appraisal (Keeney and Raiffa, 1993).
The initiatives among payers to support reasonable pricing
of medicines are based on their perceived value, compared
to available alternatives, and thereby support the principle of
rewarding and incentivizing innovation. However, this requires
a clear definition of innovation (Aronson et al., 2012; Ward
et al., 2014; Permanand and Pedersen, 2015). Examples of tools
that have been developed by payers in association with others
to improve pricing deliberations include Value Based Pricing
(VBP) and the Transparent Value Framework (TVF; European
Commission, 2012; Godman et al., 2015). There is also ongoing
research into risk models between payers and providers such as
leasing models (Crown et al., 2017). The TVF was developed
in response to concerns about the high prices being requested
for new orphan medicines and the increasing numbers being
made available (Hughes-Wilson et al., 2012; Godman et al.,
2015). Similar concerns are expressed about the rising prices of
anti-cancer drugs given increasing prevalence rates with limited
correlation between clinical benefits and prices (Ghinea et al.,
2015; Tefferi et al., 2015; Vivot et al., 2017), leading to suggestions
for developing minimum effectiveness criteria for new cancer
medicines as well as critiquing existing criteria developed by
cancer societies (Ferguson et al., 2000; Kantarjian et al., 2013;
WHO, 2015; Wild et al., 2016; Aggarwal et al., 2017). These are
based on the fact that many of the new cancer medicines appear
to have limited effect on overall survival despite high prices
(Kantarjian et al., 2013; Grössmann and Wild, 2017; Salas-Vega
et al., 2017). There are ongoing initiatives among cancer groups
to improve the valuation of new cancer medicines including
the American Society of Clinical Oncology (ASCO), European
Society for Medical Oncology (ESMO), Institute for Clinical
and Economic Review (ICER), and the National Comprehensive
Cancer Network (NCCN; Bentley et al., 2017; Cheng et al., 2017;
Shah-Manek et al., 2017). However, there are concerns with some
of these (Wild et al., 2016).
Some Member States have seen the need to adopt national
initiatives for early access to medicines such as the early access
to medicines scheme (EAMS) in the UK (Medicines Healthcare
Products Regulatory Agency, 2016; UK, 2017) and the ATU
scheme in France (ANSM, 2015). This practice is not shared by
all Member States. Pressure is also being put on governments of
certain countries to reimburse new medicines in high priority
areas such as cancer and those for orphan diseases at high
requested prices despite often limited health gain vs. existing
medicines (Hughes-Wilson et al., 2012; Simoens et al., 2013;
Haycox, 2016; Aggarwal et al., 2017; Grössmann andWild, 2017).
This includes political pressure to introduce the Cancer Drugs
Fund in the UK, with recent evidence suggesting no support
for ring fencing such monies in the future (Aggarwal et al.,
2017). The funding challenges are exacerbated by the often high
requested prices for new cancer medicines despite very low
manufacturing costs for a number of them (Hill et al., 2017).
Concerns with high prices, combined with the need to achieve
value for new medicines, has resulted in a growing number of
managed entry agreements (MEAs) among European countries
(Ferrario and Kanavos, 2013, 2015). MEAs are arrangements
between manufacturers and payers or providers which enable
access to health technologies (especially new and expensive
technologies) subject to specified conditions. MEAs include
a variety of mechanisms addressing uncertainty about the
performance of new technologies as well as managing the
adoption of technologies in order to maximize their effective
use or limiting their budget impact (WHO CCPPRP, 2017).
Although, there are more than 10 years of experience with
such schemes, there is still limited evidence in support of
their effectiveness while there are concerns with a number of
their shortcomings including the considerable economic burden
associated with a number of the schemes (Adamski et al., 2010;
Ferrario and Kanavos, 2013; Permanand and Pedersen, 2015;
Garattini and Curto, 2016; Godman et al., 2016a).
Post-authorization Activities
Once medicinal products are introduced into routine clinical
practice, their use is increasingly monitored to ensure prescribing
is in line with the recommendations and treatment is
optimized (Forslund et al., 2011, 2016; Godman et al., 2014,
2015; Troncoso and Diogene, 2014). This is part of new
comprehensive models that have been developed by payers and
their advisers across Europe to optimize the managed entry
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FIGURE 1 | Suggested model to better manage the introduction of new medicines (reproduced with the permission of Frontiers in Pharmacology; Malmstrom et al.,
2013).
of new medicines (Malmstrom et al., 2013; Godman et al.,
2015; Matusewicz et al., 2015; Permanand and Pedersen, 2015;
Figure 1). A number of medicinal products, including products
with conditional approval and orphan medicinal products,
are receiving marketing authorization when there are still
uncertainties in their efficacy and safety, and these shift these
uncertainties to the post-authorization phase (Joppi et al., 2016).
For innovation to be successful, it should reach the final
end user and it should address true unmet need (Kaplan et al.,
2013). Patients are the main beneficiaries of innovation as well
as being exposed to potential harms in the pharmaceutical
framework—this is a concept which may not always be
fully appreciated by other stakeholders of the pharmaceutical
framework.
Collaborations and Associations to
Support Early Access of Patients to New
Medicines
It is recommended by some stakeholders that regulations and
HTA be aligned particularly for the requirements of evidence
and for considerations for decision making (Bubela et al., 2015).
This is reflected by the EMA and some HTA bodies already
collaborating on initiatives for parallel EMA-HTA advice to
companies. For instance, the Shaping European Early Dialogue
(SEED) initiative involves early dialogue organized between
developers of pharmaceuticals, European HTA bodies and the
EMA (Meyer, 2015; Moseley, 2015).
The EC has also established the Commission Expert Group
on Safe and Timely Access to Medicines for Patients (STAMP),
which consists of experts from the Member States to provide
advice and expertise to the Commission Services in relation
to the implementation of EU pharmaceutical legislation and
policies and discusses national initiatives and experiences
in the field (European Commission, 2017). The EMA has
established the Priority Medicines (PRIME) scheme whereby
companies with candidate products are given early, proactive
and strengthened scientific and regulatory support by the
EMA (European Medicines Agency - PRIME, 2017). The
Innovative Medicines Initiative (IMI), which is a joint 50/50
initiative between the EC and EFPIA (European Federation of
Pharmaceutical Industries and Associations), funds the ADAPT
SMART project which involves different stakeholder groups and
studies initiatives to support early access of new medicines to
patients (ADAPTSMART8; ADAPT-SMART9).
Most stakeholders (industry, regulatory agencies, health care
professionals, patient groups) are represented through groupings
and associations. These are generally non-governmental
organizations. However, there are only a limited number of
payer organizations working together to seek ways to enhance
access to new innovative medicines whilst striving to maintain
8ADAPTSMART. Accelerated Development of Appropriate Patient Therapies – a
Sustainable Multi-stakeholder Approach from Research to Treatment-outcomes.
Available at URL: http://adaptsmart.eu/
9ADAPT-SMART. Project Overview. Available at URL: http://adaptsmart.eu/wp-
content/uploads/2015/09/ProjectOverview-IMI2-ADAPTSMART.pdf.
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universal access, e.g., the International Association of Mutual
Benefit Societies (AIM), the European Social Insurance Platform
(ESIP), and the Medicine Evaluation Committee (MEDEV;
Schuurman, 2008). The members of these organizations do not
always have adequate resources for participation in all initiatives,
which potentially impacts their mission.
Considerations of the Concept of Adaptive
Pathways by Payers
The introduction of Adaptive Pathways through the regulatory
system will impact on the other systems of the pharmaceutical
framework including the activities of payers. These changes will
include increased uncertainties within the evidence required
for HTA given the immaturity of available clinical data at the
time of evaluation; increased challenges of conducting budget
impact assessments (Sullivan et al., 2014); increased burden,
demands and costs for payers in the post-authorization phase;
requirements for increased monitoring of the effectiveness and
safety of new medicines in routine clinical practice by payers and
health service providers during the post-authorization phase and
possibly reduced safety and effectiveness of new medicines for
patients due to the level of uncertainty (Ermisch et al., 2016).
The monitoring burden is enhanced by concerns with available
IT systems among member states to robustly collect clinical
data in routine care. Increased medicines costs are also a likely
threat, with the companies typically seeking higher prices for
their new medicines than current standards (Cohen and Felix,
2014; Godman et al., 2015; Howard et al., 2015; de Bruijn et al.,
2016).
When medical products receive a conditional marketing
authorization by the EMA through the concept of Adaptive
Pathways, they will need to proceed through the subsequent
systems of the pharmaceutical framework: approval or non-
approval by reimbursement/HTA agencies when reviewing
and setting prices, approval or non-approval by payers and
willingness to adopt or not by healthcare professionals and
patients. The evaluation and implementation of the activities
related to the adoption of products approved through the concept
of Adaptive Pathways will be a challenge especially as some
aspects related to Adaptive Pathways present a paradigm shift
in the regulatory system. The assurance of risk governance,
which is guaranteed through traditionalmarketing authorization,
may be different for medicines authorized through Adaptive
Pathways (Ermisch et al., 2016). If new medicines, which attain
a traditional marketing authorization, and those with ongoing
existing uncertainties about their effectiveness and/ or safety
are going to be considered equally authorized, this will increase
uncertainty and doubt regarding the safety and effectiveness
of all new medicines authorized for patients. We know for
instance that the success rate of Phase III studies and submissions
is only ∼50%, with two thirds of terminations due to lack
of efficacy and more than 20% due to safety issues (Ermisch
et al., 2016). Consequently, it is of paramount importance to
explain the difference between adaptively and conventionally
licensed medicines to patients to make sure that they are making
informed decisions about their own treatment options. This
distinction is seen as essential in order to avoid confusion and
to prevent the spill-over of uncertainty surrounding medicines
approved through the Adaptive Pathways route to medicines
with established benefit/risk safety records. This uncertainty
and the lack of assurance offered by marketing authorization
may increase the gap and the lack of synchronization and
trust between the evaluation for marketing authorization
and the technical evaluation during HTA. HTA bodies may
increasingly feel the need to redo the evaluation of efficacy from
scratch, rather than adopting the efficacy evaluation from the
marketing authorization bodies and focusing on the effectiveness
evaluation.
The concept of Adaptive Pathways will result in earlier access
to patients in routine clinical care only if the new medicines
are reimbursed and paid for by payers. Recent experience
has shown that in practice the prices for such products will
depend on the success of price negotiations, and in some
countries a product may end up being prohibitively expensive,
or being withdrawn by the manufacturer if they consider the
price not satisfactory. Consequently, the goal of early access
may not be achieved in practice for a significant proportion
of the European population. The decision for reimbursement
and the considerations for affordability will be different in
the different member states; as a result, the uptake of the
medicines will vary between Member States (Putrik et al.,
2014). MEAs provide a possibility for consideration of different
conditions for reimbursement including risk-sharing agreements
and conditions for disinvestment; however, MEAs may not be
successful in all countries. Moreover, MEAs are not available in
every Member State or may, as mentioned, be considered too
costly to administer (Adamski et al., 2010; Ferrario and Kanavos,
2015; Ermisch et al., 2016).
For those countries and health care systems where medicines
approved through MAPPs are accepted for reimbursement, and
paid for by payers, these medicines will be available to patients.
In this case, the HTA evaluation will have to be undertaken with
considerable uncertainties and incomplete data. This will result
in a greater burden for payers including increased monitoring
of the new medicine in routine clinical care, monitoring of
prescribing against agreed guidance as well as possibly any
added conditions associated with MEAs. It will be unlikely
that pharmaceutical companies will bear the costs and the
burden formonitoring of treatment, particularly as themedicines
will be used within routine clinical practice and not under
strict controlled conditions as in Phase III trials. Thus, these
uncertainties will be borne by the different systems (including
payers and health service providers), and will be experienced
down to the patient level. If the burden and the costs for evidence
generation for dealing with uncertainties, and for monitoring
of safety and effectiveness, which are being shifted from the
pre- to the post-authorization phase, will be transferred from
pharmaceutical companies onto other stakeholders including
payers, these costs will need to be factored into any HTA
evaluation and price negotiations. This includes any costs for
necessary improvement in IT systems.
The newmedicines will need to be monitored for the duration
of the conditional approval. Once any new medicine achieves the
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required evidence, it will be re-evaluated by the EMA and the
marketing authorization will be changed to final.
If any one of the processes subsequent to the conditional
marketing authorization (pricing, reimbursement, payers, health
service providers, and healthcare professionals) does not approve
the new medicinal product, the new medicinal product will not
be accessible to patients, the ultimate beneficiary. Consequently,
for the objective of improved access to be achieved, the
perspectives and priorities of all the stakeholders involved need to
be met.
DISCUSSION
Payers will be appreciably impacted by new medicines
authorized through MAPPs. The non-binding invitation of
the EMA addressing payers to come on board “if relevant”
(European Medicines Agency, 2016) is not sufficient to
address the key issues raised by payers in their various
publications.
Within the current pharmaceutical framework, the main
changes are introduced by initiatives arising from individual
systems. For example, Adaptive Pathways have been an initiative,
a “concept”, introduced and driven by the EMA. Experience
has shown that when initiatives are pushed through one system,
the other systems which are affected will have to ensure and
protect their priorities, their sustainability and their interests. It is
important for reimbursement authorities and payers to be alerted
and to work on ways to address concerns regarding Adaptive
Pathways.
Adaptive Pathways will not necessarily result in improvement
in outcomes for patients. Any improvement has to be measured
in terms of the benefit to the ultimate beneficiaries, the patients.
The introduction of Adaptive Pathways will not address the
current issue of delay in access to new products in some
Member States due to differences in product launch bymarketing
authorization holders or due to lack of affordability.
If Adaptive Pathways are implemented, reimbursement
authorities and payers may have to make a number of
considerations. In reality, only a limited number of new
medicines offer a clinical advantage over existing medicines
and address unmet medical need (Prescrire Editorial, 2016).
There will be a requirement to establish a definition for unmet
medical need from the perspective of considering significant
gaps in the availability of treatments to patients after full
evaluation of alternative treatments which are already available.
Secondly, as the new medicines being authorized will have
gaps in evidence, and will present appreciably more uncertainty
than currently seen with traditional approaches, there will
be difficulties in carrying out robust HTA evaluations. The
procedure for HTA evaluation for products authorized through
Adaptive Pathways should not be distinctive or different from
that used for other authorized medicinal products. For legal
and equity considerations, in a number of countries it will be
considered unacceptable to treat these medicines differently from
other authorized medicines. Any procedure dealing with public
funding of medicines through Adaptive Pathways must ensure
that all medicines are evaluated to the same standards, and if they
meet these standards to a different degree, this will be ultimately
reflected in their evaluation and reimbursement.
Adaptive Pathways will not support payers to secure good
prices for new medicinal products. It seems that in spite of
the Treaties and legislation concerning public procurement,
within the EU there is no legal framework which demands full
transparency and disclosure of costs including R & D costs and
cost of goods even when these concern public funds. This lack
of transparency does not support the concept of value-based
pricing, which seems to be accepted by a number of stakeholders
(WHO, 2015; Godman et al., 2016a).
Consideration of opportunity costs could support the
achievement of the best use of available resources (Barrett
et al., 2006; Haycox, 2016). Decisions including opportunity
costs should be managed openly and transparently and involve
patients and society. This includes risk-sharing agreements and
disinvestment criteria alongside any investment decision made
under the Adaptive Pathways framework (Parkinson et al., 2015;
Guerra-Júnior et al., 2017). MEAs are likely to become even more
important, although, as mentioned, concerns exist including
their administrative burden (Adamski et al., 2010; Ferrario and
Kanavos, 2013; Ermisch et al., 2016; Garattini and Curto, 2016).
In view of this, payers should not accept different conditions
for reimbursement for new higher priced medicines authorized
via Adaptive Pathways. Differential considerations will be to the
detriment of patients whose disease conditions are as relevant
but do not happen to be in the same category. Whilst different
considerations such as specific funding and less stringent criteria
for evaluation are already happening for patients with cancer
and orphan diseases in certain countries (Simoens et al., 2013;
Cohen and Felix, 2014; Haycox, 2016), further practices of this
kind should ideally be avoided to maintain the European ideals
of comprehensive and equitable healthcare for all.
Adaptive Pathways will necessarily increase the
administrative, logistic and monitoring burden for payers,
and these parameters should be transparently factored into
any evaluation and costs. This includes any obligations and
factors associated with MEAs (Ermisch et al., 2016), including
formal disinvestment, should the perceived value of the new
medicine not be seen in practice. As medicines approved through
Adaptive Pathways will already have a marketing authorization,
pricing and reimbursement bodies will need to consider them
in line with Council Directive 89/105/EEC10 (the Transparency
Directive) adding to the burden for payers during this phase
where authorization is only provisional.
It will be challenging for payers to stratify the supply of
medicines and to restrict the use of these medicines only for the
authorized indications. The off-label use of medicines is regulated
differently in different countries. It may come with a higher risk
for adverse drug reactions (Eguale et al., 2016), and where there
is uncertainty related to efficacy and safety, the possibility of risk
may be augmented. Another challenge with the implementation
10Council Directive 89/105/EEC of 21 December 1988 relating to the transparency
of measures regulating the prices of medicinal products for human use and their
inclusion in the scope of national health insurance systems.
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of Adaptive Pathways is the collection of safety and effectiveness
data when the medicines are used in routine clinical care post-
authorization given the limited IT infrastructure in a number of
Member States. As these new medicines still have uncertainties
in knowledge regarding their effectiveness and safety in the post-
authorization phase, they will require additional studies to cover
the obligations of the conditional approval. This may require
cooperation between pharmaceutical companies and payers to
ensure that these obligations are met in a timely and informative
manner. There is still a question regarding by whom and how the
costs for monitoring, as well as the costs of medicines approved
through Adaptive Pathways, will be borne.
Granting high prices for medicines during the collection of
efficacy and effectiveness data is not an attractive option for
most payers and will be an increasing challenge. Some costs
which through the traditional approval would have been borne
by pharmaceutical companies in the pre-authorization phase will
necessarily shift to the post-authorization phase, and may have
to be borne by payers. If such added costs and burden are borne
by payers for the whole period until full marketing authorization
is granted, difficulties in funding will be increased. The period
of conditional approval is not pre-defined and may be long. In
view of this, ideally in cases of positive reimbursement decisions
by payers, launch prices should take these costs into account.
Pharmaceutical companies need to have data on medicines use in
clinical practice to fulfill their obligations to give the information
required by the regulator to shift these products from conditional
approval to full marketing authorization. This data will need
to be obtained from health service providers and payers. In
exchange, payers may have a stronger position to negotiate with
the companies during negotiations on prices and on MEAs.
There may also be more financial burden to payers because the
uncertainties associated with the effectiveness of these products
can result in greater expense if the newmedicines are less effective
and less safe than expected with more monitoring requirements.
In those situations where reimbursement authorities or payers
do not consider the reimbursement of medicines authorized
through MAPPs positively, pharmaceutical companies may
ideally consider paying for the products and supporting their
monitoring in order to collate necessary post-authorization data.
Possible collaboration of payers to streamline activities and
avoid duplication, and to enhance purchasing and negotiation
power building, is recommended. One example of such
collaboration is the Beneluxat with Belgium, Netherlands,
Luxemburg and Austria collaborating for the management of
new medicines (de Block, 2015).
If products are approved through MAPPs, it should be
ensured that all stakeholders, including healthcare professionals
and patients, are aware of the true uncertainty surrounding these
medicines. It should be ensured that adequate provision for
liability and informed consent procedures are in place so payers
are not additionally burdened by the responsibility for the benefit
or risks from the use of these new medicinal products and by any
liability costs.
It is also important that research projects and initiatives,
which are funded (fully or partially) through EU/public funds,
address the objectives of the pharmaceutical framework and
include as many different stakeholders as possible to balance
interests and perspectives. The current ADAPT SMART project is
the main (if not the only) initiative which allows communication
between the different stakeholders with regards to Adaptive
Pathways. However, some authorities may be hesitant to
participate in such initiatives due to concerns that participation
in such projects and alliances may compromise their position to
take decisions in their best national interest. Nevertheless, these
authorities need to express their views publicly—in alternative
fora, approaches or projects.
The biggest failure of the pharmaceutical system is that not all
patients between and within the Member States have equal access
to medicines. This distortion should be addressed first before
investing heavily in new, expensive medicines with limited health
gain. This is particularly important as most standard medicines
are now available as low cost generics, and increasingly as lower
cost biosimilars (Woerkom et al., 2012; Matusewicz et al., 2015;
Godman et al., 2017).
The principles of subsidiarity and conferral (referring back
to the section on Legal and Governance Structure) make
a distinction between what is the responsibility of the EC,
such as centralized marketing authorization, and what is the
jurisdiction of the Member States, such as decisions for pricing
and reimbursement. This is a major consideration which helps
to secure Member State autonomy and the ability to deal with
initiatives and changes emanating from other stakeholders of
the pharmaceutical framework. The risk governance and the
objectives set by the treaties offered by the current regulatory
framework should be secured. This is necessary particularly in
view of the lack of alignment, coordination and trust between the
different stakeholders of the pharmaceutical framework (Pharma
Diplomacy Working Group, 2016). Such uneasiness will be
exacerbated by progressing with the Adaptive Pathways process
unless it is limited to only a very few truly innovative medicines,
with issues of affordability adequately considered. However, the
“Public consultation on strengthening EU cooperation on HTA”
(European Commission Public Health, 2016) proposes possible
changes which may have an impact on the pharmaceutical
framework and its various systems.
RECOMMENDATIONS
Payers need to have plans in place on how to deal with new
medicines which will be authorized through the process of
Adaptive Pathways. If European payers do not adopt a planned
coordinated approach, they run the risk of ending up only
reacting to this initiative post factum instead of being in a
pro-active position.
New initiatives to change the pharmaceutical framework
should aim at supporting increased access to valuable and useful
medicines for all patients with true unmet medical need. Such
initiatives should be proposed starting from a level playing field
for all stakeholders. Increasing equity in the level of coverage for
patients should be a primary consideration in the discussions on
access and affordability. If the introduction of Adaptive Pathways
results in increased shift of burden onto payers, it is unlikely
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that this will adequately address the differences in the level of
availability of medicines to patients across different Member
States. Where the shift in burdens and costs result in blocking
medicinal products approved through MAPPs to reach patients,
pharmaceutical companies should bear or share these costs and
burdens. Clear explicit mechanisms to measure the impact on
true unmet medical need should be set and acted upon as part
of the MAPPs process. Consequently, there needs to be an agreed
definition of what constitutes unmet medical need.
There could be different alternatives which allow for out-
of-the-box solutions as compared to current accepted practices.
Lowering prices may lead to wider use of medicinal products.
Currently negotiations between payers and the industry lack
transparency especially if confidential discounts as part of MEAs
are part of the negotiations. It is not clear whether collaboration
between countries is possible for such negotiation procedures,
although this is already changing, and collaboration regarding
HTA activities is considered positively.
CONCLUSION
The example of Adaptive Pathways shows that different systems
and stakeholders within the pharmaceutical framework have
different priorities and objectives. This renders consensus and
strategic collaboration within and between the different systems
and stakeholders very difficult.
Clarification is required regarding a number of concerns
which have been raised by payers in previous publications.
Certain considerations which were not prioritized during the
development of the concept of Adaptive Pathways still need to
be addressed. To start with, it is important that all players are
clear and transparent about the responsibility of the different
stakeholders and authorities involved in different processes of the
pharmaceutical framework. The minimum level of uncertainty
and risk involved should be clear, and the basis for a positive
benefit/risk evaluation should be transparent. The regulatory
and governance responsibility for products with a centralized
marketing authorization legally lies with the EC. Health care
professionals and patients need to endorse and clearly accept any
additional level of risk which they may share through this new
concept.
Payers need to be prepared to deal with newmedicines granted
conditional approval through Adaptive Pathways. Payers already
have experience dealing with conditional approval but need to
address the new challenges presented. It is important that in
addition to technical considerations, payers should also adopt a
wider policy perspective. There are aspects on which payers may
benefit from collaborating.
It is likely that the level of accessibility and uptake of
new medicines introduced through Adaptive Pathways will
be different in different Member States. As experienced with
other new medicines, access to new medicines will range from
full adoption in some Member States to no access in others.
This may depend to some extent on the ability of the legal
framework in the individual Member States to accommodate the
MAPPs model. The affordability of the products, prioritization
and availability of funding are also determinants. Moreover,
pharmaceutical companies’ willingness to acknowledge the
inherent uncertainties of their MAPPs-licensed medicines by
accepting lower initial prices, and possibly by fully funding
these medicines until full approval, will also play a role. As
compared to other medicines introduced for unmet medical
need, there may be some shift in the uptake probability
curve due to the increased challenges introduced through the
regulatory process of Adaptive Pathways. Payers need to meet
these challenges in an active way. They need to respect their
responsibility toward ensuring equity in the allocation of public
resources.
MAPPs should also be closely monitored and followed up to
evaluate their actual implementation and their impact on the
outcome of addressing the true unmet medical needs of patients
in the EU.
Ideally, common agreed outcomes are established for
a coordinated strategy for new initiatives aimed to bring
about changes to the pharmaceutical framework. A holistic
approach for the pharmaceutical framework might provide
the basis to obtain a balance between the needs of all
stakeholders. Regrettably this is currently not the case.
Such coordination will require increased transparency
in the way that the different systems operate and affect
each other, and increased trust and consideration between
stakeholders.
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